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ABSTRACT
Objective: The purpose of this study was to evaluate the prevalence of Chlamydia trachomatis in our
rural obstetric population and assess the appropriateness of selective vs. universal prenatal screen-
ing.
Methods: Between April 1, 1991 and May 1, 1993, 1,587 patients were screened at their first
prenatal visit using a C. trachomatis antigen test. Patients who were unmarried, younger than 20
years of age, or had a history of a previous sexually transmitted disease (STD) were classified as
being at high risk for C. trachomatis. All others were considered low risk for C. trachomatis.
Results: The overall prevalence of C. trachomatis was 2.0%. There was a significant difference
(P < 0.001) in the 1,128 patients considered low risk [0.5%, 95% confidence interval (CI) 0.2-1.2]
compared to the 459 patients with one or more identifiable risk factors (5.7%, 95% CI 3.7-8.2).
Conclusions:Routine prenatal screening for C. trachomatis in our population is not appropriate for
low-risk patients. (C) 1994 Wiley-Liss, Inc.
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hlamydia trachomatis is the most common bac-
terial sexually transmitted disease (STD) in the
United States. Many reports have described serious
complications that may result from C. trachomatis
infection during pregnancy. C. trachomatis has been
implicated in premature rupture ofmembranes and
premature labor and associated with low birth
weight, stillbirth, and neonatal death.
1-4 In the
postpartum period, C. trachomatis has been identi-
fied as a cause of late postpartum endometritis, s It
is important to note, however, that not all studies of
C. trachomatis in pregnancy have supported the
association of C. trachomatis with any or all of these
complications. Some have found no linkage, while
others found an association only in the subset of C.
trachomatis-infected patients who are also positive
for C. trachomatis IgM antibodies.
6-1 Less con-
troversial is the neonatal infectious morbidity asso-
ciated with maternal C. trachomatis infection. Of
neonates born to mothers with untreated C. tra-
chomatis, it is estimated that 30% will develop C.
trachomat# ophthalmia neonatorum and 35% will’
develop Chlamydia pneumonia.
12 Although these
are usually benign and easily treated illnesses, ap-
proximately 25% of infants with pneumonia re-
quire hospitalization and one report has described
permanent respiratory sequelae in infants with
pneumonia.
13--14
The fact that C. trachomatis screening of preg-
nant patients and treatment of those infected can
eliminate most or all of the complications described
above has led to the recommendation for expanded
C. trachomatis screening as a worthwhile preven-
tive strategy. The Center for Disease Control
(CDC), in a 1985 bulletin, recommended that
pregnant women be screened for C. trachomatis if
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they were unmarried, younger than 20 years of
age, had a history of STDs, or had multiple sexual
partners.
15 In 1989, new recommendations were
published calling for universal rather than selective
prenatal C. trachomatis screening.
16 The Wiscon-
sin Department of Health and Social Services and
the Wisconsin Association for Perinatal Care have
also recommended that all pregnant women be
screened for C. trachomatis.
Although the cost (and ease) of C. trachomatis
screening has been reduced by the use of laboratory
techniques that do not require cell culture, it is still
significant. Furthermore, it has been shown that
the prevalence of C. trachomatis varies from one
geographic area to the next and within geographic
areas it varies according to patient risk fac-
tors. 1,5,7,18 The purpose of this study was to de-
termine whether it was appropriate, in our particu-
lar patient population, to comply with the
recommendation to screen all pregnant patients for
C. trachomatis or if we should continue our policy
of selective screening based on certain risk factors.
SUBJECTS AND METHODS
Between April 1, 1991 and May 1, 1993, all pa-
tients who enrolled for routine prenatal care at a
large multispecialty clinic in central Wisconsin were
considered eligible for this study. Patients who had
received C. trachomatis screening at other facilities
were excluded.
Each patient was interviewed at her first prena-
tal visit regarding maternal age, marital status, and
history ofSTDs. Patients were classified as being at
high risk for C. trachomatis if they were younger
than 20 years of age, unmarried (single, divorced,
separated, or widowed), or had a history of a docu-
mented STD. Classification as having had a previ-
ous STD required culture-proven gonorrhea,
chlamydia, or herpes, a positive serologic test for
syphilis or human immunodeficiency virus, or gen-
ital condylomata. Patients who had no identified
risk factors were defined as being at low risk for C.
trachomatis.
All enrolled patients, regardless of identified
risk factors, were tested for C. trachomat# at their
first prenatal visit. The Syva MicroTrak
TM Chlamy-
dia Enzyme Immunoassay (EIA) Specimen Collec-
tion Kit (Syra Company, San Jose, CA) was used to
obtain and transport the specimen as per the manu-
facturer’s recommendations. Specimens were im-
mediately transported to our in-house regional lab-
oratory which performs Chlamydia EIA studies on
a daily basis. Specimens are tested according to the
Syva Company protocol and utilize the Syva Mi-
croTrak
TM II Chlamydia EIA kit along with a Den-
ley Wellwash 4 autowasher (Denley Instruments,
Sussex, England) and Syva autoreader. Results are
reported as either positive or negative for Chlamy-
dia antigen.
Patients in the low-risk group who had positive
antigen tests were offered confirmatory cell cul-
tures. A specimen from the endocervix was ob-
tained with a sterile swab, placed in a sucrose-
phosphate broth, and transported at 4C to our
in-house laboratory. Specimens were inoculated into
McCoy cells and incubated for 48-72 h. Mono-
clonal antibody for C. trachomatis was used for
staining and the coverslips examined under fluores-
cent microscopy.
Estimates of the prevalence of C. trachomatis are
presented by risk group along with exact binomial
confidence limits. A comparison of the prevalence
for high-risk vs. low-risk patients is based upon an
exact chi-square test (CYTEL Software Corpora-
tion: Software for Exact Nonparametric Inference
User’s Manual, Cambridge, MA, 1989). The as-
sociation of 3 risk factors (marital status, age, and
history of STD) with C. trachomatis infection was
examined through a stepwise logistic regression
analysis (SAS Institute, Inc.: SAS/STAT User’s
Guide, Version 6, Cary, NC, 1989). Results were
deemed statistically significant with P < 0.05.
RESULTS
Of the 1,598 eligible prenatal patients, 11 patients
did not have C. trachomatis studies performed due
to patient refusal or the provider not obtaining a
specimen. Patient history and C. trachomatis test
results were available on the remaining 1,587 pa-
tients. By history, 1,128 (71%) of these patients
were determined to be at low risk for C. trachomatis
and 459 (29%) at high risk. In the low-risk group,
6 had a positive C. trachomatis antigen study, a
prevalence of 0.5% [95% confidence interval (CI)
0.2-1.2]. In the high-risk group, 26 had a posi-
tive C. trachomatis antigen study, a prevalence of
5.7% (95% CI 3.7-8.2). The difference between
these 2 groups was highly significant (P < 0.001).
Of the 6 patients in the low-risk group who
tested positive, 3 agreed to have confirmatory cell
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TABLE I. Prenatal Chlamydia infection by risk factors with 95% confidence intervals
History of any STD
Currently Age No
married group Frequency Percent 95% CI
Yes
Frequency Percent 95% CI
Yes 20+ 6/I,128 0.5 0.1, 1.0
<20 0/23 0.0 0.0, 14.9
No 20+ 7/167 4.4 1.7, 8.5
<20 0/I 14 8.8 4.3, 15.6
1/93 I.I 0.0, 5.9
0/2 0.0 0.0, 84.2
7/52 13.5 5.6, 25.9
I/8 12.5 0.3, 52.7
TABLE 2. Prenatal Chlamydia screening: logistic
regression analysis
Risk factor Odds ratio (95% CI) P
Unmarried 7. (2.7, 18.9) < 0.001
Age (years) 0.89 (0.82, 0.98) 0.016
History of STD 2.8 (I.2, 6.5) 0.017
cultures. Two of the 3 cultures were positive for C.
trachomatis.
Prevalence for each combination of the 3 risk
factors is shown in Table 1. Small numbers in some
cells were reflected by wide CIs. In particular,
although none of the 23 patients whose only risk
factor was maternal age younger than 20 years had a
positive study, the small number of patients pre-
cludes drawing conclusions about this group. A
stepwise logistic regression model was used to fur-
ther assess the relative importance of 3 risk factors.
Stepwise logistic regression analysis with maternal
age as a continuous variable showed all 3 risk fac-
tors to be significant (Table 2).
DISCUSSION
Several studies have evaluated the question of the
cost effectiveness of C. trachomatis screening dur-
ing pregnancy.
12,19,20 Although different method-
ologies were used, the prevalence of C. trachomatis
at which screening ofa pregnant population became
cost effective ranged from 5% to 6%. The major
difficulty in determining cost effectiveness is the
controversy and uncertainty regarding the impor-
tance of C. trachomatis in the various pregnancy
complications discussed previously. Screening costs
and the cost of caring for patients with C. trachom-
atis-related illnesses also vary. With all of this in
mind, we believe it is reasonable to assume that C.
trachomatis screening is not cost effective in a very
low-prevalence population such as our low-risk pa-
tients. Based on the results ofthis study, we propose
that the vast majority of the benefit of C. trachoma-
tis screening will be gained, at a much lower cost,
by returning to selective rather than universal
screening. This policy is also consistent with a re-
cently published Canadian study.
18
One of the criticisms of selective screening for
C. trachomatis is that providers would neglect to do
an adequate assessment of risk factors and thus not
screen all patients at risk. We decided to simplify
risk factor assessment by using only 3 of the 4 risk
factors described in the 1985 CDC recommenda-
tions. We did not include multiple sexual partners
as a risk factor because we were concerned about
our ability to objectively assess the accuracy of this
history. By limiting risk factors, for the purpose of
determining the need to screen for C. trachomatis,
the process becomes more straightforward and pro-
video" compliance will likely improve. We have
also subjected the 3 risk factors utilized for this
study to logistic regression analysis which docu-
mented the importance of each of the 3 risk (actors.
Finally, we wish to emphasize that this risk factor
assessment should not preclude the use of a provid-
er’s clinical judgment regarding C. trachomatis
screening in individual patients.
Another concern about C. trachomatis screening
is the particular screening test being used. Cell
culture remains the "gold standard" but is more
costly and associated with greater transport difficul-
ties than are non-culture techniques. Therefore,
these non-culture assays have become the most com-
mon methods ofC. trachomat# screening. Although
they have excellent sensitivity and specificity, their
specificity is still less than that of cell culture.
21
This is not a significant problem in high-preva-
lence populations, and it is not cost effective to do
confirmatory cell cultures for patients in this group
who have positive antigen tests. It does, however,
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become more important in low-prevalence popula-
tions. For example, an antigen test with a specific-
ity of98% and a sensitivity of90% when applied to
a population with a 2.5% disease prevalence has a
54% positive predictive value.
19 This led to our
decision to offer confirmatory cell cultures to low-
risk patients with positive antigen tests. That of 3
of these confirmatory cultures was negative is con-
sistent with the expected low positive predictive
value. The newer DNA polymerase methods are
reported to have the same specificity as cell culture
and their future use may thus eliminate this con-
cern.
22
Selective screening requires that one has first
determined, as was done in this study, the preva-
lence in the particular population that is presumed
to be low risk. It should not be assumed that preva-
lences in different populations are comparable. For
example, even our high-risk patients had a lower
prevalence of C. trachomatis than is usually re-
ported for high-risk groups. This may be due to
our particular patient demographics, including a
rural, central Wisconsin population in which 98%
of prenatal patients are Caucasian, 75% have pri-
vate health insurance, and 8 5% have at least a high
school education. In any case, it emphasizes the
need to base screening policies on prevalence mea-
surements from the practitioner’s own patient
group.
Once it is determined that the population desig-
nated as being at low risk does not have a preva-
lence that justifies, on a cost-effectiveness basis,
screening for C. trachomatis, the.next issue is how
one would know if that prevalence changes signifi-
cantly in the future. One option is to periodically
screen low-risk patients until enough have been
tested to indicate that the prevalence remains lower
than the level at which screening is cost effective. A
second option is to rely on statistics generated by the
State Health Department (in those states where C.
trachomatis is a reportable disease), although it is
often difficult to draw conclusions about a particu-
lar patient population from the .more general statis-
tics in these data. We have chosen a third option
which is to monitor the. prevalence of C. trachoma-
tis in the high-risk pregnancy patients and assume
that it mirrors the prevalence in low-risk patients.
Therefore, if the prevalence increases in high-risk
patients, we will need to reevaluate low-risk pa-
tients to determine if they have also experienced a
concurrent and significant increase. We also moni-
tor the number of positive C. trachomatis studies in
infants with conjunctivitis or pneumonia, and we
would reevaluate the screening protocol if there
were more than a minimal number of positive tests
(there were none over the time span of this study).
In summary, in an environment oflimited health
care resources, we believe it is appropriate to use
selective rather than universal prenatal screening
for C. trachomatis. Prerequisites for this approach
are a simple method for assessing risk, a knowledge
of the C. trachomatis prevalence in the particular
patient population determined to be low risk, and a
mechanism to follow that population for any signif-
icant change in prevalence.
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